Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver

International Journal of Biological Markers

Volumn 23, Issue 4, 2008, Pages 225-230

  Nedić, Olgica ^a   Malenkovic V ^b   Dukanovic B ^b   Baricevic I ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinical Center Bezanijska Kosa   (Yugoslavia)

Author keywords

IGF I; IGF II; IGFBP 1; IGFBP 3; Liver carcinoma

Indexed keywords

BIOLOGICAL MARKER; MITOGENIC AGENT; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; IGFBP3 PROTEIN, HUMAN; INSULIN; SOMATOMEDIN BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; INOPERABLE CANCER; LIVER CARCINOMA; LIVER FUNCTION; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT MONITORING; PRIMARY TUMOR; PROTEIN SYNTHESIS; BLOOD; CASE CONTROL STUDY; GLUCOSE BLOOD LEVEL; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 65349158363     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.3068     Document Type: Article

References (30)

1. Zumkeller W. IGFs and IGFBP-3: surrogate markers for diagnosis and surveillance of tumor growth? J Clin Pathol 2001; 54: 285-8.
2. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-54.
3. Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-78.
4. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999; 51: 34-41.
5. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006; 13: 583-92.
6. Scharf J-G, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001; 54: 138-44.
7. Shalhoub P, Kern S, Girard S, Beretta L. Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Dis Markers 2001; 17: 217-23.
8. Fan M-H, Chang AE. Resection of liver tumors: technical aspects. Surg Oncol 2002; 10: 139-52.
9. Heriot AG, Reynolds J, Marks CG, Karanjia N. Hepatic resection for colorectal metastases - a national perspective. Ann R Coll Surg Engl 2004; 86: 420-4.
10. Parasole R, Izzo F, Perrone F, et al. Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res 2001; 7: 3504-9.
11. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001; 34: 255-61.
12. Fleischer M, Dnistrian AM, Sturgeon SM, Lamerz R, Wittliff JL. Practice guidelines and recommendations for use of tumor markers in the clinic. The National Academy of Clinical Biochemistry: Laboratory Medicine Practice Guidelines, vol 15. Washington: AACC Press, 2002.
13. Morrero JA, Lok AS. Newer markers of hepatocellular carcinoma. Gastroenterology 2004; 127: S113-9.
14. Sangiovanni A, Colombo E, Radaelli F, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. Am J Gastroenterol 2001; 96: 1575-80.
15. International Federation of Clinical Chemistry, Scientific Commitee, Clinical Section. Expert Panel on Theory of Reference Values and International Committee for Standardisation in Haematology. Part 5. Statistical treatment on the theory of reference values: determination of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-56.
16. Scharf J-G, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-93.
17. Institute of Public Health of Serbia "Dr Milan Jovanovi Batut", Cancer Registry of Central Serbia: Cancer incidence and mortality in central Serbia. Report No. 4, Belgrade, 2005.
18. Fusai G, Davidson BR. Management of colorectal liver metastasis. Colorectal Dis 2003; 5: 2-23.
19. Lopez JB, Balasegaram M, Timor J, Thambyrajah V. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma. Malays J Pathol 1997; 19: 53-8.
20. Tsai JF, Jeng JE, Chuang LY, et al. Serum insulin-like growth factor-II and α-fetoprotein as tumor markers of hepatocellular carcinoma. Tumor Biol 2003; 24: 291-8.
21. Ranke MB, Maier K-P, Schweizer R, et al. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 2003; 60: 174-80.
22. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-9.
23. Dvorchik I, Carr BI. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. Cancer Detect Prev 2007; 31: 154-60.
24. Tomizawa M, Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol 2006; 12: 6531-5.
25. Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005; 14: 850-5.
26. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-18.
27. Nikolić AJ, Todorović V, Božić M, et al. Serum insulin-like growth factor (IGF)-II is more closely associated with liver dysfunction than is IGF-I in patients with cirrhosis. Clin Chim Acta 2000; 294: 169-77.
28. Nedić O, Nikolić AJ, Hajduković-Dragojlović L, Todorović V, Masnikosa R. Alteration of IGF-binding proteins in patients with liver cirrhosis. Alcohol 2003; 21: 223-9.
29. Assy N, Hochberg Z, Enat R, Baruch Y. Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I (IGF-I) and its binding protein-3 in patients with compensated and decompensated liver cirrhosis. Dig Dis Sci 1998; 6: 1317-21.
30. Frystyk J, Grøfte T, Skjærbḱ C, Ørskov H. The effect of oral glucose on serum free insulin-like growth factor-I and - II in healthy adults. J Clin Endocrinol Metab 1997; 82: 3124-7.